- Home
- AUTL vs GRAL Comparison
AUTL vs GRAL Comparison
Compare AUTL & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- GRAL
- Stock Information
- Founded
- AUTL 2014
- GRAL 2016
- Country
- AUTL United Kingdom
- GRAL United States
- Employees
- AUTL N/A
- GRAL N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- GRAL
- Sector
- AUTL Health Care
- GRAL
- Exchange
- AUTL Nasdaq
- GRAL NYSE
- Market Cap
- AUTL 625.4M
- GRAL 1.3B
- IPO Year
- AUTL 2018
- GRAL N/A
- Fundamental
- Price
- AUTL $2.41
- GRAL $46.87
- Analyst Decision
- AUTL Strong Buy
- GRAL Buy
- Analyst Count
- AUTL 5
- GRAL 3
- Target Price
- AUTL $9.32
- GRAL $31.50
- AVG Volume (30 Days)
- AUTL 2.1M
- GRAL 1.6M
- Earning Date
- AUTL 08-07-2025
- GRAL 08-12-2025
- Dividend Yield
- AUTL N/A
- GRAL N/A
- EPS Growth
- AUTL N/A
- GRAL N/A
- EPS
- AUTL N/A
- GRAL N/A
- Revenue
- AUTL $9,011,000.00
- GRAL $130,711,000.00
- Revenue This Year
- AUTL $461.76
- GRAL $19.52
- Revenue Next Year
- AUTL $112.66
- GRAL $20.37
- P/E Ratio
- AUTL N/A
- GRAL N/A
- Revenue Growth
- AUTL N/A
- GRAL 30.47
- 52 Week Low
- AUTL $1.11
- GRAL $12.33
- 52 Week High
- AUTL $5.00
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- AUTL 70.63
- GRAL N/A
- Support Level
- AUTL $2.20
- GRAL N/A
- Resistance Level
- AUTL $2.44
- GRAL N/A
- Average True Range (ATR)
- AUTL 0.12
- GRAL 0.00
- MACD
- AUTL -0.01
- GRAL 0.00
- Stochastic Oscillator
- AUTL 84.95
- GRAL 0.00
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.